RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Valeo Pharma Stock

Valeo Pharma EBIT 2024

Valeo Pharma EBIT

-6.5 M CAD

Ticker

VPH.TO

ISIN

CA91915B1085

WKN

A2PLB4

In 2024, Valeo Pharma's EBIT was -6.5 M CAD, a -62.28% increase from the -17.23 M CAD EBIT recorded in the previous year.

The Valeo Pharma EBIT history

YEAREBIT (undefined CAD)
2028e93.96
2027e81.65
2026e55.8
2025e-0.66
2024e-6.5
2023-17.23
2022-19.11
2021-12.57
2020-4.3
2019-3.74
2018-2.43
2017-2.65
2016-2.54

Valeo Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Valeo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Valeo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Valeo Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Valeo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Valeo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Valeo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Valeo Pharma’s growth potential.

Valeo Pharma Revenue, EBIT and net profit per share

DateValeo Pharma RevenueValeo Pharma EBITValeo Pharma Net Income
2028e178.07 M undefined93.96 M undefined16.79 M undefined
2027e186.41 M undefined81.65 M undefined39.49 M undefined
2026e156.42 M undefined55.8 M undefined27.15 M undefined
2025e70.4 M undefined-661,550 undefined-13.95 M undefined
2024e58.68 M undefined-6.5 M undefined-26.91 M undefined
202353.91 M undefined-17.23 M undefined-27.81 M undefined
202227.75 M undefined-19.11 M undefined-25.75 M undefined
202113.56 M undefined-12.57 M undefined-14.23 M undefined
20207.47 M undefined-4.3 M undefined-4.76 M undefined
20196.58 M undefined-3.74 M undefined-3.62 M undefined
20184.38 M undefined-2.43 M undefined-2.44 M undefined
20171.28 M undefined-2.65 M undefined-3.62 M undefined
2016985,710 undefined-2.54 M undefined-1.28 M undefined

Valeo Pharma stock margins

The Valeo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Valeo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Valeo Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Valeo Pharma's sales revenue. A higher gross margin percentage indicates that the Valeo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Valeo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Valeo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Valeo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Valeo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Valeo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Valeo Pharma Margin History

Valeo Pharma Gross marginValeo Pharma Profit marginValeo Pharma EBIT marginValeo Pharma Profit margin
2028e24.26 %52.77 %9.43 %
2027e24.26 %43.8 %21.18 %
2026e24.26 %35.67 %17.36 %
2025e24.26 %-0.94 %-19.82 %
2024e24.26 %-11.07 %-45.86 %
202324.26 %-31.96 %-51.58 %
202222.64 %-68.88 %-92.8 %
202129.17 %-92.72 %-104.99 %
202018.49 %-57.56 %-63.73 %
201921.3 %-56.82 %-54.96 %
201819.01 %-55.42 %-55.62 %
201741.52 %-207.26 %-283.27 %
201640.19 %-257.19 %-129.5 %

Valeo Pharma Aktienanalyse

What does Valeo Pharma do?

Valeo Pharma Inc is a pharmaceutical company that was founded in 2003. It is based in Montreal, Canada and its stocks are traded on the Toronto Stock Exchange. The company specializes in the development, manufacturing, and marketing of innovative pharmaceutical and medical products to help patients in Canada and around the world. Valeo Pharma's business model is based on identifying unmet medical needs, particularly in niche markets where there is a demand for innovative solutions. The company recognizes that there are difficulties for patients and healthcare professionals in finding specific medications suitable for their treatment needs in these niche markets. Valeo Pharma aims to fill this gap by developing innovative products tailored to the specific needs of patients and professionals, differentiating itself from other standard products. Valeo Pharma operates in two main business areas: Pharmaceuticals and OTC - Over-the-Counter. The pharmaceutical division of Valeo Pharma focuses on the development of drugs for the treatment of diseases that are currently inadequately treated. Their products in this area include drugs for the treatment of neurology, oncology, infectious diseases, dermatology, and psychiatry. Valeo Pharma's OTC division specializes in the development of products for self-medication and disease prevention. Their products in this area include pain relief products, cold and cough treatments, and general health support. Some of Valeo Pharma's key products include Blexten, an antihistamine for the treatment of seasonal and perennial allergic rhinitis as well as chronic idiopathic urticaria, and Redesca, a product for the prevention of blood clots and reducing the risk of thrombosis in patients with various medical conditions. Valeo Pharma has formed various partnerships with leading pharmaceutical companies around the world to bring its products to market. Through these partnerships, the company can expand its reach and offer exclusive products to its customers in different regions. Valeo Pharma is committed to research and development of new products that meet the needs of patients and healthcare professionals. The company invests in the development of active substances that treat diseases that are currently inadequately treated or have no effective medical treatments available. Overall, Valeo Pharma has established itself as a leading pharmaceutical company in Canada, focusing on providing innovative products to improve the health and well-being of patients. The company has a strong presence in the Canadian and international pharmaceutical industry and aims to expand its business through the development and marketing of innovative products and the formation of further strategic partnerships with pharmaceutical companies. Valeo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Valeo Pharma's EBIT

Valeo Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Valeo Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Valeo Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Valeo Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Valeo Pharma stock

How much did Valeo Pharma achieve in EBIT for the current year?

In the current year, Valeo Pharma has achieved an EBIT of -6.5 M CAD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Valeo Pharma.

How has the EBIT of Valeo Pharma developed in recent years?

The EBIT of Valeo Pharma has increased by -62.28% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Valeo Pharma?

The EBIT of Valeo Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Valeo Pharma pay?

Over the past 12 months, Valeo Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Valeo Pharma is expected to pay a dividend of 0 CAD.

What is the dividend yield of Valeo Pharma?

The current dividend yield of Valeo Pharma is .

When does Valeo Pharma pay dividends?

Valeo Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Valeo Pharma?

Valeo Pharma paid dividends every year for the past 0 years.

What is the dividend of Valeo Pharma?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Valeo Pharma located?

Valeo Pharma is assigned to the '-' sector.

Wann musste ich die Aktien von Valeo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Valeo Pharma from 11/5/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Valeo Pharma pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Valeo Pharma in the year 2023?

In the year 2023, Valeo Pharma distributed 0 CAD as dividends.

In which currency does Valeo Pharma pay out the dividend?

The dividends of Valeo Pharma are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Valeo Pharma

Our stock analysis for Valeo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Valeo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.